Navigation Links
Esperion Therapeutics Initiates Phase I Clinical Study for ETC-1002
Date:11/13/2009

PLYMOUTH, Mich., Nov. 13 /PRNewswire/ -- Esperion Therapeutics, a privately held biotechnology company working to discover, develop and commercialize treatments for cardiovascular and metabolic diseases, today announced that the company has initiated a Phase I clinical study for ETC-1002, the company's novel small molecule compound designed to beneficially regulate the levels of plasma lipids and lipoproteins. The single escalating dose study in healthy volunteers will be the first clinical study conducted by Esperion since the re-establishment of the company in May 2008.

ETC-1002 is being developed to treat dyslipidemia, an early-stage risk factor of coronary artery disease and associated metabolic syndromes. The compound targets lipid metabolism in two ways: first, by inhibiting fatty acid and cholesterol synthesis; and second, by enhancing oxidation of fatty acids. ETC-1002 therefore has the potential to lower LDL-C and triglycerides and also to increase HDL-C.

"Our pre-clinical research related to ETC-1002 has been very promising, and we are pleased to advance this new product candidate to clinical development. ETC-1002 is the flagship product of our dyslipidemia program, and it will also be the first product in our pipeline to reach clinical-stage development," said Roger Newton, PhD, FAHA, president and CEO of Esperion Therapeutics. "Just over a year and a half following the re-establishment of Esperion, we continue to progress toward our goal of bringing breakthrough cardiovascular and metabolic disease therapies to market."

Cardio-metabolic diseases are the leading cause of morbidity and mortality among men and women in industrialized countries around the world.

"We are very well positioned to move ahead with the development effort for ETC-1002 as we also advance our other promising pre-clinical research programs in both acute and chronic therapies to treat cardiovascular and metabolic disorders," Mr.
'/>"/>

SOURCE Esperion Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Axelar AB Presents the New Anticancer Agent AXL1717 at The AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, Massachusetts, USA
2. Hollis-Eden to Present Interim Data From Its Phase I/II Clinical Studies of Apoptone(R) (HE3235) at Molecular Targets and Cancer Therapeutics Conference
3. Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting
4. Nektar Therapeutics Reports Third Quarter 2009 Financial Results
5. Tolera Therapeutics Files IND Application for TOL101, Appoints OToole to Lead Clinical Operations
6. Amicus Therapeutics Announces Third Quarter 2009 Financial Results and Strategic Business Updates
7. Cell Therapeutics, Inc.s (CTI) Presentation at BIO Investor Forum to be Webcast
8. Oxygen Biotherapeutics, Inc. Expands Board of Directors
9. Cornerstone Therapeutics to Host Third Quarter 2009 Conference Call
10. Fate Therapeutics Announces Creation of Small Molecule Platform for Commercial Scale Reprogramming
11. Frost & Sullivan Recognizes Agile Therapeutics for Its Innovative Weekly Low-Dose Contraceptive Patch
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2015)... April 20, 2015 /CNW/ - Portage Biotech Inc. ("Portage" ... PBT.U), is pleased to announce that its wholly owned ... research study that showed one of its proprietary human-derived ... brain tissue through inhibition of NFkB signalling even if ... The permeability of the blood brain barrier (BBB) in ...
(Date:4/20/2015)... --  Meditope Biosciences, Inc ., a biotechnology company developing ... presentation of data demonstrating the use of its SnAP ... data were presented in an abstract at the AACR ... Philadelphia . "We are ... many commercial applications that may be possible for our ...
(Date:4/20/2015)... Whitehouse Laboratories is pleased and overly excited to ... and Drug Administration (FDA) inspection and received no observations ... compliance inspection, as based upon 21CFR Parts 210 and ... and was granted NAI (no action indicated) status. The ... Manufacturing Practice (GMP) quality system required by the regulatory ...
(Date:4/17/2015)... 17, 2015  Centrillion Technologies, a genomic ... from the National Human Genome Research Institute, ... (NIH). The grant will help fund the ... of breakthrough genomic technologies, including phased sequencing ... Centrillion has been developing this transformative and ...
Breaking Biology Technology:Portage's CPP Platform Delivers a Peptide Cargo Across Blood Brain Barrier 2Portage's CPP Platform Delivers a Peptide Cargo Across Blood Brain Barrier 3Meditope Biosciences Presents Data At The American Association Of Cancer Research (AACR) Annual Meeting Validating Its SnAP Technology Platform 2Whitehouse Laboratories Completes FDA Inspection with No Form 483 – No Observations 2Whitehouse Laboratories Completes FDA Inspection with No Form 483 – No Observations 3
(Date:3/23/2015)... --NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company"), ... market, announces its biometric payment technology, the Wocket® smart wallet, ... March 30 th . The new ... York markets. Gino Pereira ... new ad campaign following the recent initial shipment of Wocket ...
(Date:3/20/2015)... OXFORD, Conn. , March 20, 2015 ... "Company"), a biometric authentication company focused on the growing ... Wocket® smart wallet is one of the products featured ... today, March 20th at 11:00 PM EST on the ... travels to Las Vegas , site ...
(Date:3/18/2015)... March 18, 2015 As mobile payments ... revolutionary smart wallets and apps continue to be introduced into ... in the mobile payment industry in focus today are:  NXT-ID, ... (NYSE: BABA ), Apple Inc. (NASDAQ: ... Facebook Inc. (NASDAQ: FB ) NXT-ID, ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 2NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 3Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 2Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 3Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 4Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 5Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 6
... As a result of field work by associate professor James ... of the Ryukyus in Okinawa, Japan has found two ... in unexpected locations. The species belong to the genus ... species in the Indian Ocean. Surprisingly, the new species were ...
... articles about the Deepwater Horizon oil spill provides ... science used in the unprecedented response effort by ... behind-the-scenes look at the extensive scientific and engineering ... outside the governmentassembled to respond to the disaster. ...
... Calif., Nov. 29, 2012  Medbox, Inc. (OTC Markets: MDBX) ... their unique and patented biometric medical marijuana dispensing system ... recent days. The Medbox system provides patients with safe, ... products in states that have legal medical marijuana programs. ...
Cached Biology News:An ocean away: 2 new encrusting anemones found in unexpected locations 2Research, response for future oil spills: Lessons learned from Deepwater Horizon 2Research, response for future oil spills: Lessons learned from Deepwater Horizon 3Research, response for future oil spills: Lessons learned from Deepwater Horizon 4Medbox, Inc. Featured in Multiple Media Stories in Massachusetts and California 2Medbox, Inc. Featured in Multiple Media Stories in Massachusetts and California 3